All In Biotech

Drug Trial Radar · NCT05990738

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

DAREON™-9: A Phase Ib Open-label Dose Escalation and Dose Confirmation Safety Study of Intravenous BI 764532 in Combination With a Single Agent Chemotherapy for the Treatment of Patients With Relapsed/Refractory Small Cell Lung Cancer After Platinum-based Chemotherapy

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

69

Actual

Start

Feb 14, 2024

Primary completion

Mar 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that had previously received platinum-based chemotherapy and are eligible to receive a single agent chemotherapy treatment. The purpose of this study is to find the highest dose of BI 764532 that people can tolerate when taken together with a single agent chemotherapy. BI 764532 is an antibody-like molecule that may help the immune system fight cancer. Participants may continue to take BI 764532 as long as they benefit from treatment and can tolerate it. During this time, participants visit the study site regularly. The visits also depend on the response to the treatment. At the study visits, the doctors check the health of the participants, take necessary laboratory tests, and note any health problems that could have been caused by the study treatment.

Conditions

  • Small Cell Lung Carcinoma (SCLC)

Interventions

  • BI 764532Drug

    BI 764532

  • TopotecanDrug

    Topotecan

  • Single agent chemotherapyDrug

    single agent chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Occurrence of dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation periodTime frame: up to 9 weeks
  2. Part B: Occurrence of DLTs during the on-treatment periodTime frame: up to 36 months
  3. Part B: Occurrence of AEs during the on-treatment periodTime frame: up to 36 months

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Mayo Clinic - Florida

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • Virginia Commonwealth University

    Richmond, Virginia

  • INS Curie

    Paris, France

  • HOP Civil

    Strasbourg, France

  • Institut Gustave Roussy

    Villejuif, France

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, Germany

  • Universitätsklinikum Würzburg AÖR

    Würzburg, Germany

  • Polish Mother's Memorial Hospital - Research Institute

    Lodz, Poland

  • Leicester Royal Infirmary

    Leicester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.